Option chain shows key data for Adial Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Adial Pharmaceuticals.

Adial Pharmaceuticals (NASDAQ:ADIL) Stock, Option Chain

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

ADIL

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

Adial Pharmaceuticals secured FDA support for its AD04 bridging strategy, paving the way for Phase 3 trials in 2025 after confirming bioequivalence.

EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder

Adial Pharmaceuticals received a U.S. patent for genetic marker-based treatment methods and completed a pharmacokinetics study supporting its Phase 3 trial.

EXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals announced completion of PK study for AD04, confirming predictable bioavailability, dose proportionality, and no food effect.

EXCLUSIVE: Adial Pharmaceuticals Reveals Positive Pharmacokinetics Study Results Of AD04 For Alcohol Use Disorder

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

Press Releases

Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference

Management

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals Announces Positive Topline Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Legal

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders

Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies

Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04

Earnings

Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update

VRPX

Addex Therapeutics Ltd - American Depositary Shares

Addex Therapeutics

Akanda

Artelo Biosciences

Aytu BioPharma

Biofrontera

China Pharma Holding

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals

Enveric Biosciences

Evoke Pharma

Eyenovia

Gelteq

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

Lyra Therapeutics

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharmaceuticals

Purple Biotech Ltd. - American Depositary Shares

Purple Biotech

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Relmada Therapeutics, Inc. - Common Stock

Relmada Therapeutics

SenesTech

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

60 Degrees Pharmaceuticals, Inc. - Common Stock

60 Degrees

Talphera

Titan Pharmaceuticals, Inc. - Common Stock

Comments

Adial Pharmaceuticals

Adial Pharmaceuticals (ADIL) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga